JP2022506062A5 - - Google Patents
Info
- Publication number
- JP2022506062A5 JP2022506062A5 JP2021523218A JP2021523218A JP2022506062A5 JP 2022506062 A5 JP2022506062 A5 JP 2022506062A5 JP 2021523218 A JP2021523218 A JP 2021523218A JP 2021523218 A JP2021523218 A JP 2021523218A JP 2022506062 A5 JP2022506062 A5 JP 2022506062A5
- Authority
- JP
- Japan
- Prior art keywords
- solid formulation
- formulation according
- solid
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752685P | 2018-10-30 | 2018-10-30 | |
| US62/752,685 | 2018-10-30 | ||
| PCT/US2019/057725 WO2020092100A1 (en) | 2018-10-30 | 2019-10-23 | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506062A JP2022506062A (ja) | 2022-01-17 |
| JP2022506062A5 true JP2022506062A5 (cg-RX-API-DMAC7.html) | 2022-10-20 |
| JP7425794B2 JP7425794B2 (ja) | 2024-01-31 |
Family
ID=70464349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523218A Active JP7425794B2 (ja) | 2018-10-30 | 2019-10-23 | 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12358870B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873443A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7425794B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102991240B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112955130A (cg-RX-API-DMAC7.html) |
| MX (1) | MX418110B (cg-RX-API-DMAC7.html) |
| MY (1) | MY209101A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202104208RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092100A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| CN115697307A (zh) * | 2020-06-19 | 2023-02-03 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | 包含达普司他的制剂 |
| IL303390A (en) | 2020-12-03 | 2023-08-01 | Battelle Memorial Institute | Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| US11827614B2 (en) | 2021-05-21 | 2023-11-28 | Merck Sharp & Dohme Llc | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates |
| US20240327929A1 (en) * | 2021-08-12 | 2024-10-03 | Merck Sharp & Dohme Llc | Dosage regimen for administration of belzutifan |
| US12145901B1 (en) | 2021-09-17 | 2024-11-19 | Arcus Biosciences, Inc. | Process for preparing tetralin compounds |
| AU2023407370A1 (en) * | 2022-12-22 | 2025-07-03 | Cogent Biosciences, Inc. | Bezuclastinib formulations |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| KR102824931B1 (ko) * | 2023-10-17 | 2025-07-08 | 주식회사 참인티그레이션 | 오일 유화 공법을 이용하여 제조되는 반려동물 건강 영양제 및 이의 제조방법 |
| AU2024393766A1 (en) | 2023-12-08 | 2026-06-18 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4932412A (en) | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
| DE60038624T2 (de) | 1999-10-07 | 2009-06-10 | Aquilar-Cordova, Carlos, Estuardo, Newton | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie |
| US7115265B1 (en) | 2001-05-14 | 2006-10-03 | Duke University | Four genetic tumor markers specific for human glioblastoma |
| CN101827585A (zh) | 2007-10-19 | 2010-09-08 | 雅培股份有限两合公司 | 含有n-芳基脲基化合物的固态分散体产品 |
| US8691866B2 (en) * | 2008-12-10 | 2014-04-08 | The General Hospital Corporation | HIF inhibitors and use thereof |
| TWI673051B (zh) | 2012-09-11 | 2019-10-01 | 美商梅維森前列腺療法有限責任公司 | 恩雜魯它脈(enzalutamide)之調和物 |
| CN105307636A (zh) | 2013-07-19 | 2016-02-03 | 西佳技术公司 | 非晶形特考韦瑞制备 |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| CN113209024A (zh) | 2013-12-31 | 2021-08-06 | 阿森迪亚制药有限责任公司 | 疏水性化合物的药物组合物 |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
-
2019
- 2019-10-23 CN CN201980071770.6A patent/CN112955130A/zh active Pending
- 2019-10-23 WO PCT/US2019/057725 patent/WO2020092100A1/en not_active Ceased
- 2019-10-23 MX MX2021005038A patent/MX418110B/es unknown
- 2019-10-23 EP EP19880015.3A patent/EP3873443A4/en active Pending
- 2019-10-23 US US17/286,581 patent/US12358870B2/en active Active
- 2019-10-23 MY MYPI2021002202A patent/MY209101A/en unknown
- 2019-10-23 KR KR1020217016289A patent/KR102991240B1/ko active Active
- 2019-10-23 SG SG11202104208RA patent/SG11202104208RA/en unknown
- 2019-10-23 JP JP2021523218A patent/JP7425794B2/ja active Active
-
2025
- 2025-06-30 US US19/254,916 patent/US20250326711A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berl et al. | Oral tolvaptan is safe and effective in chronic hyponatremia | |
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法(ベムラフェニブ及びmdm2阻害剤) | |
| CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
| KR102319078B1 (ko) | 궤양성 대장염의 치료용 의약 조성물 | |
| JP2019516711A5 (cg-RX-API-DMAC7.html) | ||
| JP2005525345A5 (cg-RX-API-DMAC7.html) | ||
| EP2575783B1 (en) | Methods and compositions for oral pharmaceutical therapy | |
| JP2020514292A5 (cg-RX-API-DMAC7.html) | ||
| JP2019515908A5 (cg-RX-API-DMAC7.html) | ||
| JP2019514965A5 (cg-RX-API-DMAC7.html) | ||
| JP2016529285A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516795A (ja) | エベロリムスおよびアムセネストラントを含む組合せ物 | |
| JP2016530238A5 (cg-RX-API-DMAC7.html) | ||
| JP2017511377A5 (cg-RX-API-DMAC7.html) | ||
| JP2021535147A5 (cg-RX-API-DMAC7.html) | ||
| JP2024502446A5 (cg-RX-API-DMAC7.html) | ||
| JP2006518731A5 (cg-RX-API-DMAC7.html) | ||
| IL292770A (en) | Formulations and dosages of polyethylene glycol-modified oricase | |
| EA032067B1 (ru) | Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита | |
| US11083722B2 (en) | Combination therapies for the treatment of breast cancer | |
| US20250319084A1 (en) | Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer | |
| JP2020523317A5 (cg-RX-API-DMAC7.html) | ||
| US20170224670A1 (en) | Drug Combination to Treat Melanoma | |
| JP2020515523A5 (cg-RX-API-DMAC7.html) | ||
| JP2021503448A5 (cg-RX-API-DMAC7.html) |